Evidence map›Paper›PMID 41369232›Full record

ArticleJournal of clinical microbiology2026

Evaluation of stool-based testing to diagnose tuberculosis in children using the Truenat platform in routine settings in Nigeria.

J O Olabamiji, K Ochei, O Daniel, R Eneogu, A Ihesie, D Nongo, A Agbaje, P Dakum, E Elom, A Mwansasu and 9 more

Abstract readEvaluation StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

J O OlabamijiInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.ORCID 0009-0008-8587-4423
K OcheiUSAID Nigeria, Abuja, Nigeria.ORCID 0009-0006-0000-736X
O DanielInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.
R EneoguUSAID Nigeria, Abuja, Nigeria.ORCID 0000-0002-3616-7457
A IhesieUSAID Nigeria, Abuja, Nigeria.ORCID 0000-0002-1739-6350
D NongoUSAID Nigeria, Abuja, Nigeria.ORCID 0000-0001-5339-9818
A AgbajeInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.ORCID 0000-0002-3625-5625
P DakumInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.ORCID 0000-0003-4278-5224
E ElomNational Tuberculosis, Leprosy and Buruli Ulcer Control Programme, Abuja, Nigeria.ORCID 0000-0002-4071-3430
A MwansasuIDDS project, Washington, DC, USA.
C ColvinOffice of Infectious Disease, TB Division, Credence Management Solutions, LLC. Support contractor to USAID Bureau for Global Health, Washington, DC, USA.ORCID 0000-0003-3257-0772
N DiazOffice of Sustainable Development, Health Division, Public Health Institute, Support contractor to USAID Bureau for Africa, Washington, DC, USA.
A AdelekanInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.
S OyelaranUSAID Nigeria, Abuja, Nigeria.
C MensahInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.
O OdolaInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.
A OlayemiInstitute of Human Virology Nigeria, International Research Centre of Excellence (IRCE), BAZE University, Abuja, Nigeria.
P de HaasKNCV TB Foundation, the Hague, the Netherlands.ORCID 0000-0003-3024-0198
E KlinkenbergConnect TB, the Netherlands, consultancy services provided for USAID TB team, Washington, DC, USA.ORCID 0000-0001-7179-3595

Funding

United States Agency for International Development GS00Q14OADU119
6 · The paper itself

Abstract

The World Health Organization (WHO) recommends testing stool with Xpert MTB/RIF Ultra (Xpert-Ultra) as an initial diagnostic test for detection of tuberculosis (TB) and rifampicin resistance in children. The option of testing stool on the Truenat platform could benefit children and their caregivers in remote areas where GeneXpert is not available. We report the results of research to validate a protocol for processing and testing stool on Truenat using an adapted Simple One Step (SOS) stool method in routine settings in Nigeria. Stool specimens from children with presumptive TB were tested with Truenat MTB Plus (Truenat) and Xpert-Ultra using a comparative cross-sectional study design. A total of 510 children were enrolled and submitted a stool specimen. Of these, 482 (94.5%) had valid results on both platforms, 28 (5.8%) with MTB detected and 454 MTB not detected. Of the 28 with MTB detected, eight were detected on both platforms, seven on Truenat only, and 13 on Xpert-Ultra only. The concordance rate between Truenat and Xpert-Ultra was high at 95.8%. Significantly more non-determinate (error/invalid) results were observed with Truenat compared to Xpert-Ultra (4.7% versus 1.2% respectively;

Indexed as

FecesMolecular Diagnostic TechniquesMycobacterium tuberculosisTuberculosisAdolescentChildChild, PreschoolCross-Sectional StudiesFemaleHumansInfantMaleNigeriaSensitivity and Specificitychildhood TBchildrenhard-to-reachstoolTruenattuberculosisXpert MTB/RIF Ultra

Identifiers

PMID41369232
PMCPMC12802198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.